Weekly Research Analysts’ Ratings Changes for Ventas (VTR)

A number of firms have modified their ratings and price targets on shares of Ventas (NYSE: VTR) recently:

• 5/4/2026 – Ventas had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $100.00 price target on the stock.
• 5/4/2026 – Ventas had its price target raised by Royal Bank Of Canada from $91.00 to $98.00. They now have an “outperform” rating on the stock.
• 5/4/2026 – Ventas had its price target raised by UBS Group AG from $85.00 to $93.00. They now have a “neutral” rating on the stock.
• 5/1/2026 – Ventas had its price target raised by Citigroup Inc. from $96.00 to $100.00. They now have a “buy” rating on the stock.
• 4/29/2026 – Ventas had its “outperform” rating reaffirmed by Evercore Inc. They now have a $95.00 price target on the stock.
• 3/27/2026 – Ventas had its “buy (b-)” rating reaffirmed by Weiss Ratings.
• 3/26/2026 – Ventas had its price target raised by Wells Fargo & Company from $88.00 to $93.00. They now have an “overweight” rating on the stock.
• 3/20/2026 – Ventas had its price target raised by JPMorgan Chase & Co. from $88.00 to $93.00. They now have an “overweight” rating on the stock.

Ventas Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, April 16th. Investors of record on Tuesday, March 31st were issued a $0.52 dividend. This is a positive change from Ventas’s previous quarterly dividend of $0.48. The ex-dividend date of this dividend was Tuesday, March 31st. This represents a $2.08 dividend on an annualized basis and a yield of 2.4%. Ventas’s dividend payout ratio is currently 378.18%.

Insider Transactions at Ventas

In related news, EVP Carey S. Roberts sold 35,532 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $85.00, for a total value of $3,020,220.00. Following the completion of the transaction, the executive vice president directly owned 72,755 shares of the company’s stock, valued at $6,184,175. This represents a 32.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.53% of the stock is owned by company insiders.

Ventas, Inc (NYSE: VTR) is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.

Ventas’ business model combines property ownership with active asset management and capital markets activity.